ZEALAND PHARMA/S (ZEAL) to Release Quarterly Earnings on Thursday

ZEALAND PHARMA/S (NASDAQ:ZEAL) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 15th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last posted its quarterly earnings results on Thursday, August 16th. The company reported ($0.67) earnings per share for the quarter. The business had revenue of $2.42 million for the quarter. ZEALAND PHARMA/S had a negative net margin of 483.00% and a negative return on equity of 78.33%. On average, analysts expect ZEALAND PHARMA/S to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NASDAQ:ZEAL traded up $0.47 during trading hours on Friday, hitting $13.68. 364 shares of the company’s stock traded hands, compared to its average volume of 8,516. The firm has a market capitalization of $416.68 million, a price-to-earnings ratio of -9.24 and a beta of 2.28. ZEALAND PHARMA/S has a twelve month low of $11.51 and a twelve month high of $18.91.

ZEAL has been the topic of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $26.00 price target on shares of ZEALAND PHARMA/S in a research report on Friday, September 7th. MED reaffirmed a “positive” rating on shares of ZEALAND PHARMA/S in a research report on Thursday, September 27th. Finally, Morgan Stanley set a $29.00 target price on ZEALAND PHARMA/S and gave the stock a “buy” rating in a research report on Wednesday, September 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. ZEALAND PHARMA/S currently has a consensus rating of “Hold” and a consensus price target of $25.00.

ILLEGAL ACTIVITY NOTICE: This report was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.wkrb13.com/2018/11/09/zealand-pharma-s-zeal-to-release-quarterly-earnings-on-thursday.html.


Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Recommended Story: Retained Earnings


Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply